Changing the future of Oncology.
About Sutro Biopharma
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Platform
Precision protein engineering generates superior molecules
Products
4 product candidates in the clinic as a result of research innovations
Partners
Premier collaborations with Bristol Myers Squibb, Merck, EMD Serono and Vaxcyte (formerly known as SutroVax)
People
Great people making excellence happen, every day!
Open Letter from CEO, Bill Newell
March 31, 2021
I Stand in Support of our AAPI Community
I want to address the violence and discrimination towards our AAPI community; it has been there for hundreds of years. It is now apparent that it was, in some cases, under-reported or ignored. Most certainly it was greatly under-appreciated. However, recent news coverage of these reprehensible attacks and the resulting amplification of this evidence of violence have shown a constant spotlight on what seems to be daily instances of violence and discrimination.
We live and work in the Bay Area. We are blessed with a thriving Asian community. This community is an integral part of our Bay Area and of our Sutro identity. I have lived in ignorance about what can only be characterized as a dark underbelly of violence and discrimination against our AAPI community. I regret that I wasn’t more sensitized to these issues.
Click here to read the letter in its entirety
Technology
Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.
Pipeline
Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways.
Partnerships
Recent News
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Poster
Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial Ovarian Cancer Download Poster, CLICK HERE
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Presentation
Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial Ovarian CancerDownload Presentation, CLICK HERE
Jefferies Virtual Healthcare Conference 2021 – Presentation
Webcast, Click Here Download Presentation, Click Here
Careers and Culture
At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference in the lives of patients, both as individuals and as part of a team.
